Document is current

Article History

Received: 22 March 2022

Accepted: 7 April 2022

First Online: 21 April 2022

Declarations

:

: Not applicable.

: Not applicable.

: Not applicable.

: Paolo A. Ascierto (PAA): <i>Employment or leadership position</i>: none; <i>consultant/advisory role</i>: Bristol-Meyers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna; <i>stock ownership</i>: none; <i>research funding</i>: Bristol-Meyers Squibb, Roche-Genentech, Pfizer, Sanofi; <i>expert testimony</i>: none; <i>other remuneration</i>: none.Lisa H. Butterfield (LHB): LHB declares the following unrelated advisory activities (honoraria received): StemImmune/Calidi Scientific and Medical Advisory Board, April 6, 2017-present; Western Oncolytics, Scientific Advisory Board, 2018–2021; Torque Therapeutics, Scientific Advisory Board, 2018–2020; Khloris, Scientific Advisory Board, 2019–present; Pyxis, Scientific Advisory Board, 2019–present; Cytomix, Scientific Advisory Board, 2019–present; DCprime, Scientific Advisory Board meeting, Nov. 2020; RAPT, Scientific Advisory Board, 2020–present; Takeda, Scientific Advisor, 2020–present; EnaraBio scientific advisor, Feb. 2021.Olivera J. Finn (OJF): no conflict to disclose.Andrew Futreal (AF): Scientific Advisory Board for Scorpion Therapeutics.Omid Hamid (OH): <i>consulting/advisory boards</i>: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Roche Genentech, GSK, Immunocore, Idera, Incyte, Iovance, Janssen, Merck, Nextcure, Novartis, Pfizer, Sanofi/Regeneron, Seattle Genetics, Tempus, Zelluna; <i>speaker bureau</i>: BMS, Novartis, Pfizer, Sanofi/Regeneron; <i>contracted research (for institution)</i>: Arcus, Aduro, Akeso, Amgen, Bioatla, BMS, CytomX, Exelixis, Roche Genentech, GSK, Immunocore, Idera, Incyte, Iovance, Merck, Moderna, Merck-Serono, NextCure, Novartis, Pfizer, Rubius, Sanofi/Regeneron, Seattle Genetics, Torque, Zelluna.Theresa La Vallee (TLV): Parker Institute for Cancer Immunotherapy employment; Current employment at Coherus Biosciences; LISCure Biosciences Scientific Advisory Board, June 2020–present and stock ownership AstraZeneca; Consulting: TRex Bio, Grey Wolf Therapeutics, Exosis, BiOneCure. These are outside the scope of the submitted work. T.L. has no conflicts relating to the content of this work.Michael A. Postow (MAP): <i>consulting fees</i>: BMS, Merck, Array BioPharma, Novartis, Incyte, NewLink Genetics, Aduro, Eisai, Pfizer. Honoraria: BMS and Merck. <i>Institutional research support</i>: RGenix, Infinity, BMS, Merck, Array BioPharma, Novartis, AstraZeneca.Igor Puzanov (IP): <i>consulting/honoraria</i>: Nektar, Amgen, Roche, Oncorus; <i>advisory board</i>: Bristol-Myers Squibb, Nektar; <i>institutional clinical trial support</i>: Nektar, Idera, Oncosec, Amgen, Immunocore, Dynavax, Rubius, SQZ, ADC; <i>DSMC</i>: Nouscom; <i>stock</i>: Celldex.Jeffrey Sosman (JS): <i>research</i>: Bristol Myers Squibb, Corvous, PACT; <i>advisory board</i>: Iovance, Nektar, Apixogen.Bernard A. Fox (BAF): <i>scientific advisory board (advising/consulting)</i>: Akoya/PerkinElmer, AstraZeneca/Definiens, Bristol-Myers Squibb, CanWell, Hookipa, Incyte, Macrogenics, NeoGenomics, PrimeVax (BOD, stock), Turnstone, UbiVac, Co-founder/CEO/stock, Ultivue. <i>Research support</i>: Akoya/PerkinElmer, Bristol-Myers Squibb, Definies/AstraZeneca, Incyte, Macrogenics, NanoString, OncoSec Shimadzu, Viralytics/Merck.Patrick Hwu (PH): <i>scientific advisory board</i>: Immatics US, Inc., Dragonfly, GlaxoSmithKline, Sanofi Pasteur.